Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence.
about
MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adultsEpigenetic associations in relation to cardiovascular prevention and therapeuticsPrognosis Research Strategy (PROGRESS) 2: prognostic factor researchHomocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication biasReconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysisCorrelations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART).Vitamin food fortification today.Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trialIndian perspective on clinical aspects, usage, and guidelines of folic AcidEffects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.Role of investigating thrombophilic disorders in young stroke.Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444).MTHFR C677T polymorphism as a risk factor for vascular calcification in chronic hemodialysis patientsDistribution and determinants of plasma homocysteine levels in rural Chinese twins across the lifespanRelationship between increase of serum homocysteine caused by smoking and oxidative damage in elderly patients with cardiovascular disease.Should folic acid fortification be mandatory? No.Should folic acid fortification be mandatory? YesAntiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.Aspirin decreases the risk of depression in older men with high plasma homocysteineCombined effect of folate and adiposity on homocysteine in children at three years of age.Increasing the number of SNP loci does not necessarily improve prediction power at least in the comparison of MTHFR SNP and haplotypes.High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury.Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms resulting in suboptimal oocyte maturation: a discussion of folate status, neural tube defects, schizophrenia, and vasculopathy.Therapeutical approach to plasma homocysteine and cardiovascular risk reduction.Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.Stroke and nutrition: a review of studies.Do we know enough? A scientific and ethical analysis of the basis for genetic-based personalized nutrition.Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry.Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?Will increasing folic acid in fortified grain products further reduce neural tube defects without causing harm?: consideration of the evidence.Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis.Role of homocysteine in aortic calcification and osteogenic cell differentiationPlasma homocysteine and vascular disease in elderly patients with mental illness.Session 1: Public health nutrition. Folic acid food fortification: the Irish experience.High doses of oral folate and sublingual vitamin B12 in dialysis patients with hyperhomocysteinemia.Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function.A cost-effectiveness analysis of folic acid fortification policy in the United States.Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity.Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis.
P2860
Q21245922-52F6CF3D-EFD2-4E5F-ACD3-B9F1A5A3BB63Q26771428-6FD8C2EE-1D0C-421E-90B6-1671AD7CF8BCQ28709212-C517CB89-983F-429D-8B74-1885DCC18927Q28731901-F4202E55-C78D-418F-8F43-FBE4717D3565Q28743107-519822EC-76A3-43E4-BCDD-A0BF1E256881Q33378416-78497656-A1E8-41DF-BFEA-02FC9460E8E7Q34266425-CA1FCED5-A1D7-45FF-A227-0A748F64F42FQ34320808-E7237B36-ED3F-4F03-8743-81BC7E778A06Q34350525-B0DA9DAF-DE8B-446E-8B7B-F9341CAB930BQ34356824-3333ED08-7ADF-4184-ABEA-181678D6537AQ34573328-3947B4EE-7965-4459-83E6-35AE56EA843FQ34591566-D0700782-1E4D-4F35-85C3-E52E9D5F21F1Q34595593-A2B0ABB5-11DD-4E2C-949F-22F6F4AEC9C9Q34634854-8823EF97-9E10-41D6-A7DF-16D0B2AC741AQ34775092-C82B0265-74C6-453C-9111-1FB6422CA435Q35644123-F3489AE3-C24F-4AF1-A41D-619B47DFA212Q35843590-90AF89DD-6CD8-4EE8-B3E1-9CF1469307D1Q35843632-ED92BCBA-EE23-4C0E-8B9E-2736B6708BF6Q35992524-0BD6C3F4-5C34-4094-AE00-0C21DD85B2F5Q36203435-45A20990-11B9-4B93-8374-E54CB5949EDCQ36547079-6B1FFED3-A0D6-4FC7-907C-58F9854E021FQ36632134-13857ED2-A67E-45E7-B655-E8B840BA4AD3Q36776148-4CDE406D-F831-4314-864B-891A552FF8F4Q36817799-1836FB2A-5EAF-4BC9-A2D7-29991E714458Q36822904-137533DB-9982-4009-A185-768555082D45Q36915663-D70732D4-63CE-4A90-B3A5-14D740345C89Q36917706-772BA11B-C718-44A8-9113-3F931AB19FCFQ36947535-BCCC908E-D12A-4FC8-AE6B-CFAEB7145CE4Q36982670-326123C7-942A-44D5-93E1-F4D8B9ECE5AEQ36996491-7D7A4E45-95A9-4ED7-ACE2-76477D6180B5Q37017005-CD1C7FB0-F948-4FD7-A528-DDCD63A76168Q37081246-AD8F0E74-0EBB-4A2E-B21D-E5D749056784Q37126925-26B84EEE-CF45-46CE-82D6-1C7FE43AF0DDQ37289423-EA58680E-8D79-4945-9D0A-6C4EB31EA1F4Q37291392-1CEA2E08-E780-4867-85F9-D6BEE0352F2CQ37291946-B8E368E2-2AE3-4BF6-A601-52D5409CB7D6Q37306295-0850F8EE-C78C-4286-8B79-9E143E73E646Q37377199-6FDA2ABE-F2FB-4551-A885-B05979B1B35CQ37442791-94015A23-F539-4D9C-B870-754110DA1396Q38011260-60CEA44F-14CE-49D5-9FC9-E8CB408B8068
P2860
Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@ast
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@en
type
label
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@ast
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@en
prefLabel
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@ast
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@en
P2093
P2860
P1433
P1476
Folic acid, homocysteine, and ...... f inconclusive trial evidence.
@en
P2093
David S Wald
Malcolm Law
Nicholas J Wald
P2860
P304
P356
10.1136/BMJ.39000.486701.68
P407
P577
2006-11-01T00:00:00Z